Dupixent approved in the US as the first-ever biologic medicine …
WEB6 days ago · Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit www.DUPIXENT.com .
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB3 days ago · Sanofi expects Dupixent to achieve more than €13 billion in sales in 2024. For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
FDA approves Dupixent for chronic obstructive pulmonary disease
WEB1 day ago · The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...
Press Release: Dupixent is the first and only biologic to ... - Sanofi
WEBRegeneron Investor Relations Vesna Tosic | + 914-847-5443 | vesna.tosic@regeneron.com. Sanofi Forward-Looking Statements This press release …
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBAbout Sanofi and Regeneron’s COPD Clinical Research Program. Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role …
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBNov 27, 2023 · The European Medicines Agency is reviewing Regeneron and Sanofi’s application for Dupixent for the treatment of uncontrolled COPD with type 2 inflammation; this application is based on results from the BOREAS trial. Discussions with other regulatory authorities around the world are ongoing.
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEBRegeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s …
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEBRegeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage …
Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEBDupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in …